Clinical Trial Update: Ph I/II Study of Subcutaneously Administered Veltuzumab (hA20) in NHL and CLL [Phase 1, Phase 2]

View source ↗

Summary

Clinical trial update for subcutaneously administered veltuzumab (hA20) in non-Hodgkin lymphoma and chronic lymphocytic leukemia; study completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Lymphocytic Leukemia
• Non-hodgkin Lymphoma

Drugs mentioned

• Veltuzumab (veltuzumab)

Snippet

Sponsor: Gilead Sciences | Conditions: NHL, Lymphoma, Non-Hodgkin | Phase 1, Phase 2 | Status: COMPLETED